The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies
暂无分享,去创建一个
P. Lacolley | T. Lecompte | V. Regnault | V. Latger‐Cannard | D. Wahl | J. Max | A. Membré
[1] H. Coenraad Hemker,et al. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.
[2] P. Hogg,et al. Beta2‐glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant , 1996, British journal of haematology.
[3] H. Hemker,et al. Phenotyping the haemostatic system by thrombography--potential for the estimation of thrombotic risk. , 2004, Thrombosis research.
[4] J. Mustard,et al. Preparation of Suspensions of Washed Platelets from Humans , 1972, British journal of haematology.
[5] C. Esmon,et al. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. , 2005, Blood.
[6] H. Hemker,et al. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. , 1999, Blood.
[7] Naomi,et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. , 1995, The Journal of clinical investigation.
[8] P. Joshua,et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. , 2001, Blood.
[9] T. Barbui,et al. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. , 2003, Blood.
[10] C. Male,et al. The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant , 2005, Journal of thrombosis and haemostasis : JTH.
[11] G. M. Iverson,et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. , 2006, Arthritis and rheumatism.
[12] J. Vermylen,et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. , 2003, Blood.
[13] H. Hemker,et al. A Chromogenic Test to Determine the Procoagulant Phospholipids in Platelet-rich Plasma and Whole Blood , 1994, Thrombosis and Haemostasis.
[14] S. Rahgozar,et al. Current concepts on the pathogenesis of the antiphospholipid syndrome. , 2007, Blood.
[15] Urbaniak,et al. IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation , 1998, British journal of haematology.
[16] H. Hemker,et al. Initiating and potentiating role of platelets in tissue factor‐induced thrombin generation in the presence of plasma: subject‐dependent variation in thrombogram characteristics , 2004, Journal of thrombosis and haemostasis : JTH.
[17] P. D. de Groot,et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? , 1993, Blood.
[18] J. Kelton,et al. Serum-induced platelet procoagulant activity: an assay for the characterization of prothrombotic disorders. , 1999, The Journal of laboratory and clinical medicine.
[19] H. Hemker,et al. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. , 2007, Haematologica.
[20] K. Fujikawa,et al. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. , 1989, The Journal of biological chemistry.
[21] Y. Shoenfeld,et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.
[22] Yves Gruel,et al. Platelet activation induced by human antibodies to interleukin-8. , 2003, Blood.
[23] T. Byzova,et al. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. , 1997, The Journal of biological chemistry.
[24] T. Barbui,et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. , 2007, Blood.
[25] B. Roussel,et al. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. , 1991, Journal of immunological methods.
[26] R. Derksen,et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? , 1993 .
[27] P. D. de Groot,et al. Dimers of β2-Glycoprotein I Increase Platelet Deposition to Collagen via Interaction with Phospholipids and the Apolipoprotein E Receptor 2′* , 2003, Journal of Biological Chemistry.
[28] L. Vallar,et al. β2-glycoprotein I Binding to Platelet Microparticle Membrane Specifically Reduces Immunoreactivity of Glycoproteins IIb/IIIa , 2001, Thrombosis and Haemostasis.
[29] J. Vermylen,et al. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease , 2003, Journal of thrombosis and haemostasis : JTH.
[30] F. Guillemin,et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis , 1997, Lupus.
[31] G. FitzGerald,et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. , 1997, The Journal of clinical investigation.
[32] T. Barbui,et al. Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C , 2005, British journal of haematology.
[33] C. Sáez,et al. Circulating platelet-derived microparticles in systemic lupus erythematosus , 2005, Thrombosis and Haemostasis.
[34] S. Nomura,et al. Significance of Anti-oxidized LDL Antibody and Monocyte-derived Microparticles in Anti-phospholipid Antibody Syndrome , 2003, Autoimmunity.
[35] J. Hanly,et al. Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome. , 2000, The Journal of rheumatology.